F S&P 500
5,522.00 +5.00 (+0.09%) F Dow Jones
39,894.00 +50.00 (+0.13%) F Nasdaq
19,791.50 +40.75 (+0.21%) E-mini Russell 2000 Index Futur
2,057.40 +4.60 (+0.22%) Petróleo
81.66 +0.03 (+0.04%) Oro
2,336.00 -8.40 (-0.36%)
Candel Therapeutics, Inc. (CADL)
Fuera de horario:
Candel Therapeutics, Inc.
117 Kendrick Street
Suite 450
Needham, MA 02494
United States
617 916 5445
https://www.candeltx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 42
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. | President, CEO & Director | 1.12M | N/D | 1961 |
| Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D. | Founder & Director | 35k | N/D | 1959 |
| Dr. Francesca Barone M.D., Ph.D. | Chief Scientific Officer | 506.76k | N/D | 1978 |
| Mr. Charles Schoch | Interim CFO, Principal Accounting Officer, Treasurer & Secretary | N/D | N/D | 1985 |
| Dr. Seshu Tyagarajan Ph.D. | Chief Technical & Development Officer | 335.27k | N/D | 1968 |
| Ms. Ileen B. Winick | Chief People Officer | N/D | N/D | N/D |
| Ms. Susan Stewart J.D., L.L.M. | Chief Regulatory Officer | N/D | N/D | 1961 |
| Dr. William Garrett Nichols M.D., M.S. | Chief Medical Officer | N/D | N/D | 1969 |
Descripción
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Candel Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
